# Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration

> **NCT00889850** · PHASE1 · COMPLETED · sponsor: **Mepha Ltd.** · enrollment: 100 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)
- **DRUG:** INexium 40 mg MUPS tablets (AstraZeneca, France)

## Key facts

- **NCT ID:** NCT00889850
- **Lead sponsor:** Mepha Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2009-06-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00889850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00889850, "Esomeprazole Bioavailability Study With 40 mg Oral Single Dose Fasted and Fed Administration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00889850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*